SYNTHESIS OF NOVEL HMG-COA REDUCTASE INHIBITORS .1. NAPHTHALENE ANALOGS OF MEVINOLIN

被引：0
作者：
NOVAK, L
ROHALY, J
POPPE, L
HORNYANSZKY, G
KOLONITS, P
ZELEI, I
FEHER, I
FEKETE, J
SZABO, E
ZAHORSZKY, U
JAVOR, A
SZANTAY, C
机构：
[1] TECH UNIV BUDAPEST, INST ORGAN CHEM, SZT GELLERT TER 4, H-1521 BUDAPEST, HUNGARY
[2] HUNGARIAN ACAD SCI, CENT RES INST CHEM, H-1525 BUDAPEST, HUNGARY
[3] TECH UNIV BUDAPEST, INST GEN & ANALYT CHEM, H-1521 BUDAPEST, HUNGARY
[4] UNIV KARLSRUHE, INST ORGAN CHEM, W-7500 KARLSRUHE 1, GERMANY
[5] GEDEON RICHTER CHEM WORKS LTD, H-1103 BUDAPEST, HUNGARY
来源：
LIEBIGS ANNALEN DER CHEMIE | 1992年 / 02期
关键词：
HMG-COA REDUCTASE INHIBITORS; NAPHTHYLACETATES; PIG LIVER ESTERASE; GLUTARATE; 3-HYDROXY; LACTONES;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The title compounds 2 and their corresponding (6S) epimers 18 are prepared in several steps by starting with chiral formyl ester 5, and alpha-tetralones 10: (1) coupling reaction with the ylide generated from 11 to yield unsaturated ester 13, (2) reduction to the corresponding alcohol 14, (3) addition of the Grignard reagent derived from 14 to formyl ester 5 to afford the hydroxy esters 16 and 17, and (4) lactonization. This procedure is also used to synthesize the beta-naphthyl analogs 29 and 30. Some results obtained from HMG-CoA reductase inhibitor screening are also reported.
引用
收藏
页码：145 / 157
页数：13
相关论文
共 50 条
  • [31] The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk
    Alberto Corsini
    Cardiovascular Drugs and Therapy, 2003, 17 : 265 - 285
  • [32] GENERALIZED ECZEMATOUS SKIN RASH POSSIBLY DUE TO HMG-COA REDUCTASE INHIBITORS
    KRASOVEC, M
    ELSNER, P
    BURG, G
    DERMATOLOGY, 1993, 186 (04) : 248 - 252
  • [33] Robotic inhibition assay for determination of HMG-CoA reductase inhibitors in human plasma
    Fang, W
    Liu, L
    Hsieh, JYK
    Zhao, J
    Matuszewski, BK
    Rogers, JD
    Dobrinska, MR
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2002, 16 (05) : 209 - 215
  • [34] Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors
    Kubota, T
    Fujisaki, K
    Itoh, Y
    Yano, T
    Sendo, T
    Oishi, R
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (12) : 2175 - 2186
  • [35] The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
    Corsini, A
    CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (03) : 265 - 285
  • [36] Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients
    Martin, Jill E.
    Cavanaugh, Teresa M.
    Trumbull, Leslie
    Bass, Maryetta
    Weber, Fredrick, Jr.
    Aranda-Michel, Jaime
    Hanaway, Michael
    Rudich, Steven
    CLINICAL TRANSPLANTATION, 2008, 22 (01) : 113 - 119
  • [37] INFLUENCES OF PRAVASTATIN AND SIMVASTATIN, HMG-COA REDUCTASE INHIBITORS, ON MYOCARDIAL STUNNING IN DOGS
    ICHIHARA, K
    SATOH, K
    ABIKO, Y
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 (06) : 852 - 856
  • [38] Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors
    Langone, AJ
    Chuang, P
    TRANSPLANTATION, 2006, 81 (05) : 804 - 807
  • [39] Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
    Kajinami, K
    Takekoshi, N
    Saito, Y
    CARDIOVASCULAR DRUG REVIEWS, 2003, 21 (03): : 199 - 215
  • [40] Involvement of agmatine in antidepressant-like effect of HMG-CoA reductase inhibitors in mice
    Rahangdale, Sandip
    Fating, Rajshree
    Gajbhiye, Mona
    Kapse, Mona
    Inamdar, Nazma
    Kotagale, Nandkishor
    Umekar, Milind
    Taksande, Brijesh
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 892
12345